Online Survey – Self-management for patients with Adrenal Insufficiency
Wording below credit to The Pituitary Foundation:
This research study is looking for adults in the UK with adrenal insufficiency. Researchers are looking to understand the factors that affect how people with adrenal insufficiency manage their condition and treatments. This will guide the development of an online self-management programme, and give an insight on current patient education and care servives in the UK.
The survey will take around 20-30 minutes to complete, and as a thank you the research team are donating £3 for every survey completed to The Pituitary Foundation and Addison’s Disease Self Help Group.
To complete the survey click here: Adrenal Insufficiency Self-management: Pilot Study (qualtrics.com)
If you have further queries or you would like a hard copy of the survey (including a pre-paid envelope to return) please contact: Dr Sofia Llahana – sofia.llahana@city.ac.uk.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...